Learn how the next billion-dollar acquisition will affect the innovation landscape in the pharmaceutical industry.
Join Gene Quinn, IPWatchdog.com and Marco Richter, LexisNexis PatentSight as they show you how the $74 billion deal between Bristol-Myers Squibb and Celgene may disrupt the crowded market for innovative cancer treatments.
What you will learn in this webinar:
how to spot acquisition targets
analyzing future scenarios of M&A
the impact of advanced patent analytics for due diligence evaluations
how to model divestiture scenarios and their effect on the technology landscape